Warfarin users appear more likely to develop brain bleeding following stroke treatment

March 8, 2010

Patients already taking warfarin who develop an acute stroke appear more likely to experience a brain hemorrhage following treatment with an intravenous clot-dissolving medication, even if their blood clotting function appears normal, according to a report posted online today that will appear in the May print issue of Archives of Neurology.

Intravenous tissue plasminogen activator (tPA), a clot-dissolving medication, is effective for acute and generally results in improved clinical outcomes despite a slightly higher risk of brain hemorrhage, the authors write as background information in the article. Risk of hemorrhage is increased in some populations, including older adults and those with more severe strokes, high blood glucose levels, lower platelet counts and .

Use of anti-clotting medications, such as aspirin or warfarin, before having a stroke has raised further concerns about risk of hemorrhage. However, current American Heart Association/American Stroke Association guidelines permit the use of tPA in these patients as long as their results on blood clotting tests meet an international standard (described as an international normalized ratio of less than 1.7). Shyam Prabhakaran, M.D., M.S., of Rush University Medical Center, Chicago, and colleagues studied 107 patients (average age 69.2) with who were treated with tPA between 2002 and 2009.

Of the patients, 13 (12.1 percent) were taking warfarin; all had an international normalized ratio of less than 1.7. "The overall rate of symptomatic intracerebral hemorrhage was 6.5 percent, but it was nearly 10-fold higher among patients taking warfarin compared with those not taking warfarin at baseline (30.8 percent vs. 3.2 percent, respectively)," the authors write. "Baseline warfarin use remained strongly associated with symptomatic intracerebral hemorrhage after adjusting for relevant co-variates, including age, atrial fibrillation, National Institutes of Health Scale score and international normalized ratio."

Several mechanisms may explain this association, the authors note. The clot-dissolving effects of tPA may be enhanced by the clot-preventing effects of warfarin, even at low levels. In addition, the effects of last for an average of three days after the last dose, so the international normalized ratio may continue to increase following treatment with tPA.

Given the small size and other limitations of the study, it should "serve as a hypothesis-generating report that requires confirmation in larger cohorts," the authors conclude. "Further analysis including more extensive adjustment for confounding variables in larger data sets may prove useful."

More information: Arch Neurol. 2010;67[5]. doi:10.1001/archneurol.2010.25

Related Stories

Recommended for you

Computations of visual motion in the brain

May 22, 2017

Botond Roska and his group at the FMI have elucidated how the retina and the visual cortex work together in visual motion perception. They found that cortical cells, which respond preferentially to backward image motion, ...

Understanding the architecture of our 'second brain'

May 19, 2017

Scientists have made an important step in understanding the organisation of nerve cells embedded within the gut that control its function - a discovery that could give insight into the origin of common gastrointestinal diseases, ...

Flies the key to studying the causes of dementia

May 19, 2017

A research team from the University of Plymouth, University of Southampton and the Alexander Fleming Biomedical Sciences Research Center, Vari, Greece, have studied two structurally-similar proteins in the adult brain and ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.